Medical Condition News

RSS

Hope for heterotopic ossificiation

A recent United States Army study found that excessive bone growth, also known as heterotopic ossificiation (HO), affects up to 70 percent of soldiers who are severely wounded during combat. A much smaller percentage of the civilian population also suffers from HO following trauma or invasive surgery. The excessive bone forms within muscles and other tissues causing severe pain, reduced mobility and even local paralysis if untreated.

24 Sep 2009

Adolescent depression and anxiety: Two distinct psychiatric disorders

Adolescent depression and anxiety disorders are two distinct psychiatric disorders, according to Dr. William W. Hale III (a researcher of the Langeveld Institute for the Study of Education and Development in Childhood and Adolescence at Utrecht University) in a recent publication in the Journal of Child Psychology and Psychiatry.

24 Sep 2009

Also in global health news: Malawi HIV/AIDS fight; cancer in developing world

Tim Gilbo, the World Bank's director in Malawi, announced on Tuesday that the organization will grant the country $30 million, which will be used to "increase access to prevention, treatment and mitigation services with a focus on behavioural change," SAPA/News24.com reports. Gilbo also said the country should "identify and promote those programmes that are working and drop or redesign those that are not bearing any fruits." UNAIDS Malawi coordinator Desmond Johns said HIV/AIDS is "arguably the single consistent threat in overall development" for Malawi (9/22).

24 Sep 2009

Research study links high-fructose diet to increased blood pressure in men

A high-fructose diet raises blood pressure in men, while a drug used to treat gout seems to protect against the blood pressure increase, according to research reported at the American Heart Association's 63rd High Blood Pressure Research Conference.

24 Sep 2009

Researchers visualize vasculature within native liver cyst walls of human ADPKD patients

As part of an effort to develop effective medical therapies that block the progression of liver cyst growth in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD), researchers at the University of Colorado Anschutz Medical Center have found that the liver cyst walls develop and maintain a vasculature as they grow out from the body of the liver and that factors released by epithelial cells that line the liver cyst wall lumen can drive the proliferation and development of vascular endothelial cells.

24 Sep 2009

ImmunoCellular Therapeutics completes humanization of its ICT-37 and ICT-109 antibody candidates

ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today that it has completed humanization of ICT-37 and ICT-109.

23 Sep 2009

Oxygen Biotherapeutics to commence Phase II-b trial of Oxycyte in treating traumatic brain injury

Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) today announced that the company has received approval from Israel's Ministry of Health to begin a Phase II-b, dose escalation, clinical trial in that country for use of Oxycyte(R) in traumatic brain injury (TBI). Oxycyte is the Company's perfluorocarbon (PFC) therapeutic oxygen carrier.

23 Sep 2009

The ThermoDox and MR-HIFU program shows great promise for treating life-threatening cancers

Royal Philips Electronics (NYSE: PHG; AEX: PHI) and Celsion Corporation (NASDAQ: CLSN) today announced that their joint research program to evaluate ThermoDox® in combination with MR-HIFU (Magnetic Resonance guided High Intensity Focused Ultrasound) as a combination therapy to non-invasively treat difficult cancers has successfully completed the feasibility stage.

23 Sep 2009

Results of Phase 3 CRYSTAL study of mCRC patients announced

The retrospective CRYSTAL analysis was conducted as a result of an effort to increase the tissue ascertainment rate to determine the K-ras status of patients’ tumors. The analysis included extended patient follow up of nearly 1.5 years and doubled the tissue ascertainment rate from 45% to 89%. These data are an update from the overall survival results from CRYSTAL that were published in the April 2009 issue of the New England Journal of Medicine.

23 Sep 2009

Interactive campaign to raise awareness on breast cancer

This week, Yoplait, in partnership with Susan G. Komen for the Cure, launched Know Your Girls, an interactive campaign that empowers young women to learn about breast cancer risk factors -- and then share this knowledge with their circle of friends.

23 Sep 2009

Pluristem commences dosing in Phase I clinical trial for the treatment of critical limb ischemia

Pluristem Therapeutics Inc. (NasdaqCM: PSTI; DAX: PJT) today announced the dosing of the first patient in the U.S. with its placenta-derived stem cell product, PLX-PAD, the Company’s leading candidate, in a Phase I clinical trial for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD).

23 Sep 2009

Phase 2 trial results of Bayer's Nexavar in combination with capecitabine announced

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the full results from their first collaborative group-sponsored randomized, double-blind, placebo-controlled Phase 2 trial showing that Nexavar(R) (sorafenib) tablets in combination with the oral chemotherapeutic agent, capecitabine, significantly extended progression-free survival in patients with advanced breast cancer.

23 Sep 2009

New drug test promises to yield quick and effective response for cancer therapy

A group of scientists from Hamburg may have taken a big step towards more effective cancer drug development, Europe's largest cancer congress, ECCO 15 - ESMO 34 [1], heard today (Wednesday 23 September). Dr Ilona Schonn, Director of Cell Culture Research at Indivumed GmbH, told the conference that they had developed a preclinical drug test platform that would enable researchers to analyse tumour tissue for individual patient drug responses on the molecular level.

23 Sep 2009

Improved respiratory health in Mexican women who use vented stoves

Women in Central Mexico who used a vented stove instead of the traditional indoor open fire, experienced improved respiratory health on par with a pack-a-day smoker kicking the habit, according to a recent study.

23 Sep 2009

Phase 1b interim clinical trial results of IMO-2055, Tarceva and Avast combination announced

Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).

23 Sep 2009

Researchers make significant advances in the treatment of metastatic malignant melanoma

Researchers have made significant advances in the treatment of metastatic malignant melanoma - one of the most difficult cancers to treat successfully once it has started to spread - according to a study to be presented at Europe's largest cancer congress, ECCO 15 - ESMO 34, in Berlin on Thursday.

23 Sep 2009

CANCER Research UK updates its patient information website

CANCER Research UK is to unveil its revamped award-winning patient information website, CancerHelp UK (www.cancerhelp.org.uk), in November.

23 Sep 2009

LFA launches new campaign for FDA-approved medication specifically for lupus

It's been 50 years since the U.S. Food and Drug Administration (FDA) approved a medication to treat lupus -- when Dwight D. Eisenhower was President! To highlight the need for safer, more tolerable, and effective medications, the Lupus Foundation of America, Inc. (LFA) today launched its new campaign, Band Together for Lupus(SM), which encourages people to wear an LFA purple wristband until there is a medication approved specifically for lupus by the FDA.

23 Sep 2009

New TAXUS Liberté Stent demonstrates superior results for treating long lesions

Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced that its corporate partner, Boston Scientific Corporation (NYSE: BSX), has released comprehensive data from the TAXUS ATLAS clinical program, a series of global, prospective, single-arm trials evaluating the TAXUS(R) Liberté(R) Paclitaxel-Eluting Stent System in a variety of lesions and patient groups. Three-year results from the TAXUS ATLAS Small Vessel and Long Lesion Trials continue to show significant advantages for the newer TAXUS Liberté Stent when compared to the first-generation TAXUS(R) Express(R) Stent.

23 Sep 2009

Ambassador Nancy G. Brinker calls for a global fight against cancer

The leader of the global breast cancer movement today warned of a coming wave of cancer deaths and told global health ministers to be “fearless and united” in addressing the growing cancer crisis, particularly in developing countries.

23 Sep 2009

Medical Condition News

Hope for heterotopic ossificiation

Adolescent depression and anxiety: Two distinct psychiatric disorders

Also in global health news: Malawi HIV/AIDS fight; cancer in developing world

Research study links high-fructose diet to increased blood pressure in men

Researchers visualize vasculature within native liver cyst walls of human ADPKD patients

ImmunoCellular Therapeutics completes humanization of its ICT-37 and ICT-109 antibody candidates

Oxygen Biotherapeutics to commence Phase II-b trial of Oxycyte in treating traumatic brain injury

The ThermoDox and MR-HIFU program shows great promise for treating life-threatening cancers

Results of Phase 3 CRYSTAL study of mCRC patients announced

Interactive campaign to raise awareness on breast cancer

Pluristem commences dosing in Phase I clinical trial for the treatment of critical limb ischemia

Phase 2 trial results of Bayer's Nexavar in combination with capecitabine announced

New drug test promises to yield quick and effective response for cancer therapy

Improved respiratory health in Mexican women who use vented stoves

Phase 1b interim clinical trial results of IMO-2055, Tarceva and Avast combination announced

Researchers make significant advances in the treatment of metastatic malignant melanoma

CANCER Research UK updates its patient information website

LFA launches new campaign for FDA-approved medication specifically for lupus

New TAXUS Liberté Stent demonstrates superior results for treating long lesions

Ambassador Nancy G. Brinker calls for a global fight against cancer

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News